Literature DB >> 8324643

Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.

K Ooi1, T Ohkubo, H Kuwabara, M Higashigawa, H Kawasaki, H Kakitoh, Y Kagawa, S Inagaki, K Sumida, M Sakurai.   

Abstract

We examined the effects of timing of administration of etoposide on cytosine arabinoside (ara-C) incorporation into DNA in L1210 ascites tumor. At 1 hr after injection of ara-C, 3-hr and 6-hr pretreatments with 15 mg/kg of etoposide increased ara-C incorporation to more than 200% as compared to that of ara-C given alone. Simultaneous administration of etoposide, however, decreased ara-C incorporation to 33% of that of ara-C alone. These results might explain the previously reported sequence dependency of the antitumor effect of etoposide and ara-C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324643     DOI: 10.3109/07357909309018870

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.

Authors:  M Higashigawa; D C Cao; K Matsui; S Yamada; H Kakitou; Y Kagawa; H Inamochi; M Ido; M Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.

Authors:  Akira Horikoshi; Kazuhiro Takei; Yoshifumi Hosokawa; Shigemasa Sawada
Journal:  Int J Hematol       Date:  2008-01-30       Impact factor: 2.490

3.  Modulation of the effect of 1-beta-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells.

Authors:  Y Kawai; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.